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ABSTRACT
Infiltrating myeloid derived suppressor cells and tumor-associated macrophages (TAMs) are important
components of the immunosuppressive tumor microenvironment. We recently reported that tasquinimod,
which binds to S100A9, impairs both infiltration and function of these cells. Here we discuss the
underlying mechanisms responsible for targeting multiple suppressive populations and the modulation of
the tumor microenvironment.
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Suppressive myeloid cells (SMCs), including myeloid-derived
suppressor cells (MDSCs) and TAMs, are associated with
tumor progression and metastasis.1 MDSCs expand and accu-
mulate in many cancers,1 whereas TAMs are differentiated
from immature monocytes or MDSCs when these precursors
infiltrate and adapt to the tumor environment.2 Both MDSCs
and TAMs are critical components of the immunosuppressive
tumor microenvironment that can directly inhibit activation
and function of T and NK cells.3 Therefore, modulating and/or
depleting these cells in the tumor environment is expected to
help counteracting SMC-associated immunosuppression,
tumor progression, and metastasis.
Previous reports have shown different approaches to deplete
MDSCs or to affect their expansion.4 While reduction of
peripheral MDSCs has been observed, few of these efforts have
been able to reduce infiltration of MDSCs in the tumor sites or
impair their suppressive function.4 Tasquinimod is an orally
active synthetic quinoline-3-carboxamide derivate that has
shown effect in a phase II clinical trial in patients with castra-
tion resistance prostate cancer (CRPC).5 We have recently
reported that tasquinimod reduced tumor-infiltrating MDSCs
and M2 polarized macrophages and impaired the suppressive
function of these infiltrating myeloid cells in two different
experimental cancer models, namely the CR Myc-CaP prostate
cancer model and the B16-5T4 melanoma model.6 Combining
tasquinimod with two different immunotherapy strategies in
these models clearly showed an enhanced effect on tumor
growth in both models. Interestingly, tasquinimod did not
affect accumulation of MDSCs in the peripheral sites in CR
Myc-CaP model, but slightly reduced MDSCs in spleen in the
B16-5T4 model, suggesting that modulation of SMCs in tumors
is sufficient to facilitate immunotherapies.
The composition and suppressive function of tumor-infil-
trating myeloid cells are usually different from those of periph-
eral SMCs. In the CR Myc-CaP prostate cancer model,
Gr1+CD11b+ MDSCs accumulate in peripheral blood with
tumor growth. Gr1lowCD11b+ and Gr1¡ CD11b+ immature
monocytes are also present in peripheral blood.6 In CR Myc-
CaP tumors, Gr1+CD11b+ MDSCs are one of the major popu-
lations, and Ly6G+Ly6C¡ granulocytic MDSCs are the major
subpopulation. However, the majority of tumor-infiltrating
Gr1¡ CD11b+ cells are F4/80+ macrophages (up to 80% of
CD11b+ cells), and most of these are M2 polarized TAMs.6 We
have compared the suppressive function of peripheral and
tumor-infiltrating myeloid cells. The CD11b+ cells isolated
from Myc-CaP tumors efficiently inhibited T cell proliferation
upon CD3 and CD28 stimulation,6 whereas the CD11b+ cells
from spleen did not have inhibitory effect on T cell prolifera-
tion upon the same stimulation (data not shown). These obser-
vations are consistent with another report showing that tumor
and peripheral site MDSCs have different functions.7 Impor-
tantly, we observed that tasquinimod treatment not only
reduced CD206+Arginase-1high M2 macrophages, but also
induced iNOShigh macrophages with M1 polarized phenotype.
This indicates that tasquinimod may switch the differentiation
of tumor-infiltrating macrophages from M2 polarized immu-
nosuppressive phenotype to M1 phenotype. As compared to
infiltrating MDSCs, M2 polarized TAM may represent an even
more important component of tumor-promoting, immunosup-
pressive environment. To confirm our hypothesis, we isolated
infiltrating myeloid cells from vehicle or tasquinimod-treated
tumors from donor mice, and mixed them with fresh tumor
cells to make inoculates in recipient mice. We observed that
transferred SMCs from tasquinimod-treated tumor were less
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supportive of tumor growth.6 The analysis of the composition
of tumor immune microenvironment specific to different mod-
els or diseases of interest may be critical to develop effective
strategies to modulate the environment and facilitate the devel-
opment of antitumor therapies.
Our study provides clues to the underlying mechanism for
myeloid cell modulation by tasquinimod (Fig. 1). S100A9 is a
potential target of tasquinimod that may be involved in immu-
nomodulatory activity,8 and S100A9 has been shown to regu-
late accumulation of MDSCs.4,9 Tasquinimod binds to
S100A9,10 and blocks the interaction of this ligand with its
receptors, including receptor for advanced glycation end prod-
uct (RAGE) and Toll-like receptor (TLR)-4 and EMMPRIN. In
an additional metastatic model, we observed that tasquinimod
was able to dramatically reduce M2 macrophages in renal cell
tumors and at the metastatic site (lung; unpublished data). This
observation suggests that tasquinimod may act through inhibit-
ing the trafficking of MDSCs, via inhibition of S100A9, into the
tumor in our tested models. However, a previous report showed
that antibody against RAGE, mAbGB3.1, inhibited the accu-
mulation of MDSCs in peripheral sites, but not in the meta-
static tumor site (the primary tumors were resected).4 The
discrepancy between these results may originate from the fact
that tasquinimod binds and inhibits the ligand, S100A9,
whereas mAbGB3.1 blocks one of receptors for the ligand,
RAGE. Therefore, the other receptor for S100A9, TLR4 and/or
EMMPRIN, may mediate the SMC-targeting activity of tasqui-
nimod. At the same time, other tumor or stroma-secreted
inflammatory factors may still induce peripheral MDSC expan-
sion when S100A9 protein ligand is blocked. We have also
demonstrated that expression of suppressive function-related
genes, Arginase-1 (reduction) and iNOS (induction) was
regulated by tasquinimod treatment. It has been reported that
TLR-4 pathway is an important regulator of Arginase-1 expres-
sion. This finding would suggest that tasquinimod may affect
function and polarization of SMCs by inhibiting S100A9–
TLR4–Arginase axis. Though tasquinimod did not change
accumulation of Gr1CCD11bC MDSCs in blood, it depleted
Gr1¡CD11bC monocytes from peripheral blood. Therefore,
tasquinimod may also reduce the CD206C M2 TAMs through
depletion of these Gr1¡CD11bC precursor cells from blood.
In summary, tasquinimod is an agent that has the potential
of overcoming the suppressive tumor environment. Targeting
the suppressive tumor microenvironment continues to be an
active field of exploration to address management of metastatic
cancers as part of immuno-oncology at large.
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